http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Kymera Therapeutics Announces Second Quarter 2021 Financial Results and Provides a Business Update
-
Kymera Therapeutics Announces Second Quarter 2021 Financial Results and Provides a Business Update
-
Kymera Therapeutics Appoints Karen Weisbach as Vice President, People and Culture and Jolly Bhatia as Vice President, Quality
-
Kymera Therapeutics Appoints Karen Weisbach as Vice President, People and Culture and Jolly Bhatia as Vice President, Quality
-
Kymera Therapeutics Presents New Preclinical Data on STAT3 Degraders Showing Antitumor Activity in STAT3 Mutant and Wild-Type Peripheral T-Cell Lymphoma at 13th Annual T-Cell Lymphoma Forum
-
Kymera Therapeutics Presents New Preclinical Data on STAT3 Degraders Showing Antitumor Activity in STAT3 Mutant and Wild-Type Peripheral T-Cell Lymphoma at 13th Annual T-Cell Lymphoma Forum
-
Kymera Therapeutics (KYMR) Announces Positive Interim Results from Single Ascending Dose Phase 1 Trial of KT-474 Demonstrating Degrader Proof-of-Mechanism
-
Kymera Therapeutics Announces Positive Interim Results from Single Ascending Dose Phase 1 Trial of KT-474 Demonstrating Degrader Proof-of-Mechanism
-
Kymera Therapeutics Announces Positive Interim Results from Single Ascending Dose Phase 1 Trial of KT-474 Demonstrating Degrader Proof-of-Mechanism
-
Kymera Therapeutics Appoints Elaine Caughey, MBA, as Chief Business Officer
-
Kymera Therapeutics Appoints Elaine Caughey, MBA, as Chief Business Officer
-
Kymera Therapeutics Presents New Preclinical Data for its IRAKIMiD Degrader KT-413 Demonstrating Strong Antitumor Activity as Both Monotherapy and in Combination in MYD88-mutant Lymphoma Models
-
Kymera Therapeutics Presents New Preclinical Data for its IRAKIMiD Degrader KT-413 Demonstrating Strong Antitumor Activity as Both Monotherapy and in Combination in MYD88-mutant Lymphoma Models
-
Kymera Therapeutics to Present New Data Demonstrating both Single-agent and Combination Regressions in MYD88-mutant Lymphoma Preclinical Models with IRAKIMiD Degrader KT-413 at 16th ICML Meeting
-
Kymera Therapeutics to Present New Data Demonstrating both Single-agent and Combination Regressions in MYD88-mutant Lymphoma Preclinical Models with IRAKIMiD Degrader KT-413 at 16th ICML Meeting
-
Kymera Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference
-
Kymera Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference
-
Kymera Therapeutics (KYMR) Presents New Data Demonstrating Proof-of-Degradation Using Novel Tissue-Restricted E3 Ligase
-
Kymera Therapeutics Presents New Data Demonstrating Proof-of-Degradation Using Novel Tissue-Restricted E3 Ligase
-
Kymera Therapeutics Presents New Data Demonstrating Proof-of-Degradation Using Novel Tissue-Restricted E3 Ligase
-
Kymera Therapeutics (KYMR) Presents Late-Breaking Preclinical Data on IRAK4 Degrader KT-474 at IMMUNOLOGY2021 Annual Meeting
-
Kymera Therapeutics Presents Late-Breaking Preclinical Data on IRAK4 Degrader KT-474 at IMMUNOLOGY2021™ Annual Meeting
-
Kymera Therapeutics Presents Late-Breaking Preclinical Data on IRAK4 Degrader KT-474 at IMMUNOLOGY2021™ Annual Meeting
-
Kymera Therapeutics Announces First Quarter 2021 Financial Results and Provides a Business Update
-
Kymera Therapeutics Announces First Quarter 2021 Financial Results and Provides a Business Update
-
Kymera Therapeutics Appoints Juliet Williams, PhD, as Senior Vice President, Head of Biology
-
Kymera Therapeutics Appoints Juliet Williams, PhD, as Senior Vice President, Head of Biology
-
Vyant Bio (VYNT) Announces Newly Appointed Board of Directors
-
Vyant Bio Announces Newly Appointed Board of Directors
